These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11978158)

  • 21. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring.
    Layton D; Pearce GL; Shakir SA
    Drug Saf; 2001; 24(9):703-13. PubMed ID: 11522122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure of tolterodine to treat clozapine-induced nocturnal enuresis.
    English BA; Still DJ; Harper J; Saklad SR
    Ann Pharmacother; 2001; 35(7-8):867-9. PubMed ID: 11485135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
    Malone-Lee J; Shaffu B; Anand C; Powell C
    J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolterodine and memory: dry but forgetful.
    Womack KB; Heilman KM
    Arch Neurol; 2003 May; 60(5):771-3. PubMed ID: 12756144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [An example of interactions between SSRI preparations and tolterodine?].
    von Segebaden C
    Lakartidningen; 2001 May; 98(18):2234. PubMed ID: 11402608
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probable interaction between tolterodine and warfarin.
    Taylor JR
    Pharmacotherapy; 2006 May; 26(5):719-21. PubMed ID: 16718947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities.
    Mahanta K; Medhi B; Kaur B; Narasimhan KL
    J Pediatr Urol; 2008 Apr; 4(2):118-23. PubMed ID: 18631906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P; Kaplan S; De Koning Gans HJ; Millard R
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyponatremia associated with tolterodine therapy.
    Madewell KA; Kuo P
    Am J Health Syst Pharm; 2008 Jun; 65(11):1054-6. PubMed ID: 18499879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Overactive bladder. New anticholinergic drug controls urinary urge].
    MMW Fortschr Med; 2004 Jul; 146(27-28):51. PubMed ID: 15526670
    [No Abstract]   [Full Text] [Related]  

  • 33. Tolterodine immediate release improves sexual function in women with overactive bladder.
    Hajebrahimi S; Azaripour A; Sadeghi-Bazargani H
    J Sex Med; 2008 Dec; 5(12):2880-5. PubMed ID: 18785896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transient memory impairment and hallucinations associated with tolterodine use.
    Tsao JW; Heilman KM
    N Engl J Med; 2003 Dec; 349(23):2274-5. PubMed ID: 14657444
    [No Abstract]   [Full Text] [Related]  

  • 35. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Olshansky B; Serra DB
    Clin Pharmacol Ther; 2008 Feb; 83(2):231-2; author reply 233. PubMed ID: 18043690
    [No Abstract]   [Full Text] [Related]  

  • 38. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary incontinence management: new questions from old assumptions.
    DuBeau CE
    J Am Geriatr Soc; 2001 Jun; 49(6):829-30. PubMed ID: 11454125
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.